» Authors » Steven Gallinger

Steven Gallinger

Explore the profile of Steven Gallinger including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 541
Citations 30786
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Aronson M, Palma L, Semotiuk K, Nuk J, Pollett A, Singh H, et al.
J Med Genet . 2025 Mar; PMID: 40081873
Background: Lynch syndrome (LS) is an autosomal dominant cancer predisposition syndrome caused by a germline pathogenic variant, or epigenetic silencing, of a mismatch repair (MMR) gene, leading to a wide...
2.
Binkowski B, Klamer Z, Gao C, Staal B, Repesh A, Tran H, et al.
Sci Adv . 2025 Mar; 11(10):eadt0029. PMID: 40053601
Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays for early disease detection. We hypothesized that PDAC cell subpopulations could be identified by aberrant glycan signatures in...
3.
Diaz-Gay M, Dos Santos W, Moody S, Kazachkova M, Abbasi A, Steele C, et al.
medRxiv . 2025 Mar; PMID: 40034755
Colorectal cancer incidence rates vary geographically and have changed over time. Notably, in the past two decades, the incidence of early-onset colorectal cancer, affecting individuals under the age of 50...
4.
Beaudry F, Li Z, Borgida A, Zorigtbaatar A, Wang X, Hildebrand M, et al.
Curr Oncol . 2025 Feb; 32(2). PMID: 39996880
Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making in a...
5.
McHugh K, Pai R, Grant R, Gallinger S, Davison J, Ma C, et al.
Mod Pathol . 2025 Jan; 38(5):100712. PMID: 39826799
Claudin 18.2 (CLDN18.2) immunohistochemical (IHC) expression can be used to select patients with gastric/gastroesophageal junction adenocarcinomas for zolbetuximab (IMAB362) therapy, zolbetuximab (IMAB362) being a monoclonal antibody targeting CLDN18.2. The aim...
6.
Walker R, Joo J, Mahmood K, Clendenning M, Como J, Preston S, et al.
Transl Oncol . 2025 Jan; 52:102266. PMID: 39793275
Background: Colorectal cancers (CRCs) from people with biallelic germline likely pathogenic/pathogenic variants in MUTYH or NTHL1 exhibit specific single base substitution (SBS) mutational signatures, namely combined SBS18 and SBS36 (SBS18+SBS36),...
7.
Thomas C, Takashima Y, Wesselink E, Ugai T, Steinfelder R, Buchanan D, et al.
Front Immunol . 2025 Jan; 15:1505896. PMID: 39763680
Background: Microsatellite instability-high (MSI-high) tumors comprise ~15% of sporadic colorectal cancers (CRC) and are associated with elevated T cell infiltration. However, the universality of this response across T cell subtypes...
8.
Garg B, Khan S, Courelli A, Panneerpandian P, Sheik Pran Babu D, Mose E, et al.
Cancer Res . 2025 Jan; 85(6):1049-1063. PMID: 39745352
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid cancers; thus, identifying more effective therapies is a major unmet need. In this study, we characterized the super-enhancer (SE) landscape...
9.
MacInnis R, Jenkins M, Milne R, John E, Daly M, Andrulis I, et al.
JNCI Cancer Spectr . 2024 Dec; 9(1). PMID: 39673461
Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing...
10.
Correa-Medero R, Pai R, Ebare K, Buchanan D, Jenkins M, Phipps A, et al.
PLoS One . 2024 Nov; 19(11):e0303415. PMID: 39576760
Advancement of AI has opened new possibility for accurate diagnosis and prognosis using digital histopathology slides which not only saves hours of expert effort but also makes the estimation more...